Loading
The 2017 validation of the residual cancer burden score, which graded how much triple-negative tumour is left after pre-surgery chemotherapy and found ten-year relapse-free survival of 86 percent with no residual tumour, 81 percent with minimal, 55 percent with moderate and 23 percent with extensive residual disease.
Symmans, Wei, Gould, Yu and colleagues measured the continuous residual cancer burden index (pathological complete response is 0; residual disease falls into RCB-I, II and III) and yp-stage in five prospectively followed cohorts: three receiving paclitaxel then fluorouracil, doxorubicin and cyclophosphamide (219, 262 and 342 patients), one receiving FAC alone (132) and one receiving trastuzumab with paclitaxel and FEC (203), with median event-free follow-up of 13.5, 9.1, 6.8, 16.4 and 7.1 years. Continuous residual cancer burden was prognostic within each subset independent of other variables, and RCB classes stratified risk overall, within subsets and within yp-stage. Ten-year relapse-free survival for pathological complete response, RCB-I, RCB-II and RCB-III was 86, 81, 55 and 23 percent for triple-negative disease; 83, 97, 74 and 52 percent for hormone receptor-positive/HER2-negative disease; and 95, 77, 47 and 21 percent in the trastuzumab cohort.
Turned residual disease from yes or no into a graded score; RCB II and III are now the entry criteria for post-neoadjuvant trials (ASCENT-05, TROPION-Breast03) and the population the ctDNA-guided idea targets.
Shares Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy, Residual cancer burden (RCB), Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative and the tag tnbc-evidence.
Shares ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative, Residual cancer burden (RCB), Neoadjuvant / adjuvant / perioperative, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology and the tag tnbc-evidence.
Shares MD Anderson Cancer Center, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative, Residual cancer burden (RCB), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative, Residual cancer burden (RCB), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.